OIG evaluators designed studies using sophisticated data analytics to identify questionable billing by retail pharmacies, prescribers with aberrant patterns, individuals writing prescriptions without authority to prescribe, and Schedule II drugs billed as refills. These studies generated numerous law enforcement leads, resulting in multiple ongoing investigations.

comments of Gary Cantrell, Deputy Inspector General for Investigations for the Office of Inspector General (OIG), U.S. Department of Health and Human Services (HHS) to the House Ways and Means Committee.

Read entire statement here